Stefano Gentileschi

Dr. Stefano Gentileschi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Claudia FabianiClaudia Fabiani
Claudia Fabiani
AVAntonio Vitale
Antonio Vitale
GEGiacomo Emmi
Giacomo Emmi
GLGiuseppe Lopalco
Giuseppe Lopalco
LVLorenzo Vannozzi
Lorenzo Vannozzi
LCLuca Cantarini
Luca Cantarini

17 May 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FRfor the “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology)
for the “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology)
JSJurgen Sota
Jurgen Sota
AVAntonio Vitale
Antonio Vitale
AIAntonella Insalaco
Antonella Insalaco
PSPaolo Sfriso
Paolo Sfriso
LCLuca Cantarini
Luca Cantarini

24 October 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
AVAntonio Vitale
Antonio Vitale
AIAntonella Insalaco
Antonella Insalaco
PSPaolo Sfriso
Paolo Sfriso
GLGiuseppe Lopalco
Giuseppe Lopalco
GEGiacomo Emmi
Giacomo Emmi
LCLuca Cantarini
Luca Cantarini
Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA was administered in 421 (80.04%) courses, CAN in 105 (19.96%). Sixty-two (32.1%) patients had been treated with both agents. IL-1 inhibitors were employed in 38 different indications (37 with ANA, 16 with CAN). Off-label use was more frequent for ANA than CAN (p < 0.0001). ANA was employed as first-line biologic approach in 323 (76.7%) cases, while CAN in 37 cases (35.2%). IL-1 inhibitors were associated with corticosteroids in 285 (54.18%) courses and disease modifying anti-rheumatic drugs (DMARDs) in 156 (29.65%). ANA dosage ranged from 30 to 200 mg/day (or 1.0–2.0 mg/kg/day) among adults and 2–4 mg/kg/day among children; regarding CAN, the most frequently used posologies were 150mg every 8 weeks, 150mg every 4 weeks and 150mg every 6 weeks. The frequency of failure was higher among patients treated with ANA at a dosage of 100 mg/day than those treated with 2 mg/kg/day (p = 0.03). Seventy-six patients (14.4%) reported an adverse event (AE) and 10 (1.9%) a severe AE. AEs occurred more frequently after the age of 65 compared to both children and patients aged between 16 and 65 (p = 0.003 and p = 0.03, respectively). Conclusions: IL-1 inhibitors are mostly used off-label, especially ANA, during adulthood. The high frequency of good clinical responses suggests that IL-1 inhibitors are used with awareness of pathogenetic mechanisms; adult healthcare physicians generally employ standard dosages, while pediatricians are more prone in using a weight-based posology. Dose adjustments and switching between different agents showed to be effective treatment strategies. Our data confirm the good safety profile of IL-1 inhibitors.

11 August 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Claudia FabianiClaudia Fabiani
Claudia Fabiani
AVAntonio Vitale
Antonio Vitale
Donato RiganteDonato Rigante
Donato Rigante
GEGiacomo Emmi
Giacomo Emmi
ABAlice Bitossi
Alice Bitossi
LCLuca Cantarini
Luca Cantarini

27 September 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
AVAntonio Vitale
Antonio Vitale
GEGiacomo Emmi
Giacomo Emmi
GLGiuseppe Lopalco
Giuseppe Lopalco
SGStefano Gentileschi
Stefano Gentileschi
ESElena Silvestri
Elena Silvestri
LCLuca Cantarini
Luca Cantarini

26 August 2017 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
Claudia FabianiClaudia Fabiani
Claudia Fabiani
JSJurgen Sota
Jurgen Sota
AVAntonio Vitale
Antonio Vitale
Donato RiganteDonato Rigante
Donato Rigante
GEGiacomo Emmi
Giacomo Emmi
LCLuca Cantarini
Luca Cantarini
Background/aims Adalimumab (ADA) has been shown to be an effective treatment for Behçet’s disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated. Methods We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA. Results 54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9% and 63.5%, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47). Conclusions ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy.